Medical Device | June 30, 2022
NADMED brings first CE-marked NAD+ analysis kit to the market
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Subscribe To Our Newsletter & Stay Updated
